Literature DB >> 10627549

Characterization of a panel of insertion mutants in human cytomegalovirus glycoprotein B.

J Singh1, T Compton.   

Abstract

Glycoprotein B (gB; gpUL55) of human cytomegalovirus (HCMV) plays a critical role in virus entry and cell-to-cell spread of infection. To define the structure-function relationships in gB, a panel of linker-insertion mutations was generated throughout the coding region. This strategy yielded a panel of 22 mutants with four amino acid insertions and 3 large truncation mutants. Assessment of the mutant proteins' biosynthetic properties and folding patterns analyzed in context with predicted secondary features revealed novel insights into gB's structure and trafficking properties. All of the insertion mutants were able to assemble into oligomers, suggesting that oligomerization is tolerant of small insertions and/or that multiple regions of the protein may be involved. Computer algorithm predictions of gB's secondary structure indicate that the furin-recognized cleavage site falls within an exposed loop. This loop may be particularly sensitive to structural alterations, since insertions upstream and downstream of the cleavage site rendered the mutant proteins cleavage defective. In addition, a strong correlation existed between terminal folding and cleavage of gB. Interestingly, terminal folding was not correlated with delivery to the cell surface but may influence the rate of transport to the cell surface. Nine mutants, containing insertions in both the extracellular and intracellular portions of gB, retained wild-type structural properties. This panel of characterized gB mutants, the first of this type for an HCMV protein, will be a useful tool in dissecting the role of gB during HCMV infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10627549      PMCID: PMC111473          DOI: 10.1128/jvi.74.3.1383-1392.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Towards a definition of the HCMV entry pathway.

Authors:  T Compton
Journal:  Scand J Infect Dis Suppl       Date:  1995

2.  Synthesis and processing of the envelope gp55-116 complex of human cytomegalovirus.

Authors:  W J Britt; D Auger
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

3.  Characterization of a human cytomegalovirus glycoprotein complex (gcI).

Authors:  D R Gretch; R C Gehrz; M F Stinski
Journal:  J Gen Virol       Date:  1988-06       Impact factor: 3.891

Review 4.  Function of glycoprotein B homologues of the family herpesviridae.

Authors:  L Pereira
Journal:  Infect Agents Dis       Date:  1994-02

5.  Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system.

Authors:  R B DuBridge; P Tang; H C Hsia; P M Leong; J H Miller; M P Calos
Journal:  Mol Cell Biol       Date:  1987-01       Impact factor: 4.272

6.  Human cytomegalovirus DNA sequences with homologies to the cellular genome.

Authors:  R Rüger; G W Bornkamm; B Fleckenstein
Journal:  J Gen Virol       Date:  1984-08       Impact factor: 3.891

7.  Monoclonal antibodies to human cytomegalovirus: three surface membrane proteins with unique immunological and electrophoretic properties specify cross-reactive determinants.

Authors:  L Pereira; M Hoffman; D Gallo; N Cremer
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

8.  Constitutive expression of human cytomegalovirus glycoprotein B (gpUL55) with mutagenized carboxy-terminal hydrophobic domains.

Authors:  M Reschke; B Reis; K Nöding; D Rohsiepe; A Richter; T Mockenhaupt; W Garten; K Radsak
Journal:  J Gen Virol       Date:  1995-01       Impact factor: 3.891

9.  Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus.

Authors:  W J Britt
Journal:  Virology       Date:  1984-06       Impact factor: 3.616

10.  Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus.

Authors:  M P Cranage; T Kouzarides; A T Bankier; S Satchwell; K Weston; P Tomlinson; B Barrell; H Hart; S E Bell; A C Minson
Journal:  EMBO J       Date:  1986-11       Impact factor: 11.598

View more
  9 in total

1.  Processing of human cytomegalovirus UL37 mutant glycoproteins in the endoplasmic reticulum lumen prior to mitochondrial importation.

Authors:  Manohara S Mavinakere; Chad D Williamson; Victor S Goldmacher; Anamaris M Colberg-Poley
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  Antigenic domain 1 is required for oligomerization of human cytomegalovirus glycoprotein B.

Authors:  William J Britt; Michael A Jarvis; Derek D Drummond; Michael Mach
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  Identification of functional domains in herpes simplex virus 2 glycoprotein B.

Authors:  Wei Li; Tanja J Minova-Foster; Daniel D Norton; Martin I Muggeridge
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

4.  Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  James M Binley; Rogier W Sanders; Aditi Master; Charmagne S Cayanan; Cheryl L Wiley; Linnea Schiffner; Bruce Travis; Shawn Kuhmann; Dennis R Burton; Shiu-Lok Hu; William C Olson; John P Moore
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  Disulfide bond configuration of human cytomegalovirus glycoprotein B.

Authors:  Matthew Lopper; Teresa Compton
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Analysis of Epstein-Barr virus glycoprotein B functional domains via linker insertion mutagenesis.

Authors:  Jessica J Reimer; Marija Backovic; Charuhas G Deshpande; Theodore Jardetzky; Richard Longnecker
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

7.  Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.

Authors:  Xinle Cui; Zhouhong Cao; Shuishu Wang; Ronzo B Lee; Xiao Wang; Haruhiko Murata; Stuart P Adler; Michael A McVoy; Clifford M Snapper
Journal:  Vaccine       Date:  2018-08-03       Impact factor: 3.641

Review 8.  Development of novel vaccines against human cytomegalovirus.

Authors:  Xinle Cui; Clifford M Snapper
Journal:  Hum Vaccin Immunother       Date:  2019-04-24       Impact factor: 3.452

9.  Single Chain Antibodies Against gp55 of Human Cytomegalovirus (HCMV) for Prophylaxis and Treatment of HCMV Infections.

Authors:  Bahareh Moazen; Elahe Ebrahimi; Foroogh Nejatollahi
Journal:  Jundishapur J Microbiol       Date:  2016-03-15       Impact factor: 0.747

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.